{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:5845"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:5845","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"The expression and function of TWEAK and FN14 in liver fibrosis","abstract":"Liver disease is the fifth largest cause of mortality and is the only major cause of death still increasing in the UK every year. Liver disease is often associated with increased deposition of extracellular matrix, which leads to fibrosis and in many cases progresses to end stage cirrhosis. Hepatic stellate cells (HSC) are considered to be one of the main contributors to liver fibrosis. Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) is a multifunctional TNF superfamily cytokine that signals through fibroblast growth factor-inducible 14 (Fnl4). TWEAK/Fnl4 signalling has been primarily associated with liver progenitor cell proliferation. In this thesis I demonstrate that expression of both Fnl4 and TWEAK were elevated in acute and chronic human liver injury, and co-localised with markers of activated HSCs. Fn14 expression was low in quiescent HSCs but was significantly induced in HSCs activated \\(in\\) \\(vitro\\), which could be further enhanced with TGF-β. Stimulation with recombinant TWEAK induced proliferation, but not activation of HSCs. Fnl4 gene expression was also significantly upregulated in CC14 models of hepatic injury while TWEAK KO, but not Fn14 KO, mice showed significantly reduced levels of liver fibrosis following acute and chronic CC1\\(_4\\) injury \\(in\\) \\(vivo\\). Furthermore, low soluble TWEAK levels in serum levels of PSC patients were an independent risk factor for death or transplantation. Overall these studies demonstrate a previously undescribed role of TWEAK in directly mediating liver fibrosis making it a potential therapeutic target in fibrotic liver disease.","abstract_html":"Liver disease is the fifth largest cause of mortality and is the only major cause of death still increasing in the UK every year. Liver disease is often associated with increased deposition of extracellular matrix, which leads to fibrosis and in many cases progresses to end stage cirrhosis. Hepatic stellate cells (HSC) are considered to be one of the main contributors to liver fibrosis. Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) is a multifunctional TNF superfamily cytokine that signals through fibroblast growth factor-inducible 14 (Fnl4). TWEAK/Fnl4 signalling has been primarily associated with liver progenitor cell proliferation. In this thesis I demonstrate that expression of both Fnl4 and TWEAK were elevated in acute and chronic human liver injury, and co-localised with markers of activated HSCs. Fn14 expression was low in quiescent HSCs but was significantly induced in HSCs activated \\(in\\) \\(vitro\\), which could be further enhanced with TGF-β. Stimulation with recombinant TWEAK induced proliferation, but not activation of HSCs. Fnl4 gene expression was also significantly upregulated in CC14 models of hepatic injury while TWEAK KO, but not Fn14 KO, mice showed significantly reduced levels of liver fibrosis following acute and chronic CC1<span class=\"etd-inline-math\"><sub>4</sub></span> injury \\(in\\) \\(vivo\\). Furthermore, low soluble TWEAK levels in serum levels of PSC patients were an independent risk factor for death or transplantation. Overall these studies demonstrate a previously undescribed role of TWEAK in directly mediating liver fibrosis making it a potential therapeutic target in fibrotic liver disease.","abstract_has_math":true,"creators":["Wilhelm, Annika"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2015,"date_issued":"2015-07","date_published":"2015-07","updated_at":"2026-11-19T09:28:38Z","subjects":["RC Internal medicine"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/5845/1/Wilhelm15PhD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A5845","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["na"]},{"key":"dc:creator","label":"Author","values":["Wilhelm, Annika"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2015-07"]},{"key":"dc:date.issued","label":"Date","values":["2015-07"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","School of Immunity and Infection"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/5845/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["RC Internal medicine"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/5845/1/Wilhelm15PhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Liver disease is the fifth largest cause of mortality and is the only major cause of death still increasing in the UK every year. Liver disease is often associated with increased deposition of extracellular matrix, which leads to fibrosis and in many cases progresses to end stage cirrhosis. Hepatic stellate cells (HSC) are considered to be one of the main contributors to liver fibrosis. Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) is a multifunctional TNF superfamily cytokine that signals through fibroblast growth factor-inducible 14 (Fnl4). TWEAK/Fnl4 signalling has been primarily associated with liver progenitor cell proliferation. In this thesis I demonstrate that expression of both Fnl4 and TWEAK were elevated in acute and chronic human liver injury, and co-localised with markers of activated HSCs. Fn14 expression was low in quiescent HSCs but was significantly induced in HSCs activated \\(in\\) \\(vitro\\), which could be further enhanced with TGF-β. Stimulation with recombinant TWEAK induced proliferation, but not activation of HSCs. Fnl4 gene expression was also significantly upregulated in CC14 models of hepatic injury while TWEAK KO, but not Fn14 KO, mice showed significantly reduced levels of liver fibrosis following acute and chronic CC1\\(_4\\) injury \\(in\\) \\(vivo\\). Furthermore, low soluble TWEAK levels in serum levels of PSC patients were an independent risk factor for death or transplantation. Overall these studies demonstrate a previously undescribed role of TWEAK in directly mediating liver fibrosis making it a potential therapeutic target in fibrotic liver disease."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["The expression and function of TWEAK and FN14 in liver fibrosis"]}]}],"canonical_facts":{"dc:contributor.sponsor":["na"],"dc:creator":["Wilhelm, Annika"],"dc:date":["2015-07"],"dc:date.issued":["2015-07"],"dc:description.abstract":["Liver disease is the fifth largest cause of mortality and is the only major cause of death still increasing in the UK every year. Liver disease is often associated with increased deposition of extracellular matrix, which leads to fibrosis and in many cases progresses to end stage cirrhosis. Hepatic stellate cells (HSC) are considered to be one of the main contributors to liver fibrosis. Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) is a multifunctional TNF superfamily cytokine that signals through fibroblast growth factor-inducible 14 (Fnl4). TWEAK/Fnl4 signalling has been primarily associated with liver progenitor cell proliferation. In this thesis I demonstrate that expression of both Fnl4 and TWEAK were elevated in acute and chronic human liver injury, and co-localised with markers of activated HSCs. Fn14 expression was low in quiescent HSCs but was significantly induced in HSCs activated \\(in\\) \\(vitro\\), which could be further enhanced with TGF-β. Stimulation with recombinant TWEAK induced proliferation, but not activation of HSCs. Fnl4 gene expression was also significantly upregulated in CC14 models of hepatic injury while TWEAK KO, but not Fn14 KO, mice showed significantly reduced levels of liver fibrosis following acute and chronic CC1\\(_4\\) injury \\(in\\) \\(vivo\\). Furthermore, low soluble TWEAK levels in serum levels of PSC patients were an independent risk factor for death or transplantation. Overall these studies demonstrate a previously undescribed role of TWEAK in directly mediating liver fibrosis making it a potential therapeutic target in fibrotic liver disease."],"dc:format":["application/pdf"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/5845/1/Wilhelm15PhD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","School of Immunity and Infection"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/5845/"],"dc:subject":["RC Internal medicine"],"dcterms:accessrights":["public"],"dc:title":["The expression and function of TWEAK and FN14 in liver fibrosis"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"]},"updated_at":"2026-11-19T09:28:38Z"}